glp-1 physiology informs the pharmacotherapy of obesity Frontiers GLP-1-based therapies for diabetes, obesity

Potential targets being explored for AD gene therapies include amyloid pathway intermediates and the modulation of enzymes, tau protein downregulation, APOE4 downregulation and APOE2 upregulation, neurotrophin expression, and inflammatory cytokine alteration (Lennon et al., 2021)

The ideal candidate will also have a healthy endocrine system, not be pregnant or breastfeeding, and have no history of severe low blood sugar

it's rapid weight loss without adequate nutritional support

You may be a suitable candidate if you: Have a BMI over 30 (or over 27 with weight-related health issues like high blood pressure, diabetes, or other cardiovascular risk factors) Struggle with food cravings and portion control Have insulin resistance or prediabetes Are looking for a long-term weight loss solution without dangerous side effects These medications are not a quick fix, but they provide lasting results when paired with healthy lifestyle habits

Brown A, McArdle P, Taplin J, Unwin D, Unwin J, Deakin T, et al